Faruqi & Faruqi urges Aardvark Therapeutics investors to seek legal counsel
News provided byAardvark Therapeutics · 2 min read
Faruqi & Faruqi, LLP, a leading national securities law firm, has urged Aardvark Therapeutics (NASDAQ: AARD) investors to seek legal counsel before the October 13, 2026, deadline for naming a lead plaintiff in a federal securities class action lawsuit.
The lawsuit, which was filed on behalf of a class of investors who purchased or acquired Aardvark securities, alleges that the company and its executives violated federal securities laws by making false and misleading statements. Specifically, the complaint suggests that the safety of Aardvark's drug ARD-101 was misrepresented, leading to overinflated clinical, regulatory, and commercial prospects for the drug.
According to the complaint, Aardvark's public statements were materially false and misleading throughout the Class Period, which ran from February 13, 2025, to May 14, 2026. The firm also notes that ARD-101 was less safe than the company and its executives had led investors to believe.
Following the alleged corrective disclosures, Aardvark's stock price dropped by approximately 32% on May 15, 2026. Investors who purchased or acquired Aardvark securities during the Class Period are urged to contact Faruqi & Faruqi, LLP to discuss their legal rights and potential claims.
Faruqi & Faruqi, LLP, with offices in New York, Pennsylvania, California, and Georgia, has a long history of representing investors in securities litigation and has recovered hundreds of millions of dollars for shareholders. The firm can be reached directly at 877-247-4292 or 212-983-9330 (Extension 1310) by partner Josh Wilson.
To serve as lead plaintiff, investors must file a motion with the court by October 13, 2026. Any member of the putative class may choose to serve as lead plaintiff through counsel of their choice or remain an absent class member. The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery.
Investors who wish to participate in the lawsuit can call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Extension 1310). The firm will provide legal advice and guidance on the lead plaintiff process at no cost or obligation.
For updates on the case, follow Faruqi & Faruqi, LLP on LinkedIn, X, or Facebook.